| Identification | Back Directory | [Name]
2-Pyrrolidinone, 1-[4-[(3,4-dihydro-4-methyl-1(2H)-quinoxalinyl)sulfonyl]phenyl]- | [CAS]
1448427-02-8 | [Synonyms]
PAWI-2
2-Pyrrolidinone, 1-[4-[(3,4-dihydro-4-methyl-1(2H)-quinoxalinyl)sulfonyl]phenyl]- | [Molecular Formula]
C19H21N3O3S | [MOL File]
1448427-02-8.mol | [Molecular Weight]
371.45 |
| Hazard Information | Back Directory | [Uses]
PAWI-2 is a p53-Activator and Wnt Inhibitor. PAWI-2 inhibits β3-KRAS signaling independent of KRAS. PAWI-2 selectively inhibits phosphorylation of TBK1. PAWI-2 activates apoptosis (activation of caspase-3/7), and induces PARP cleavage. PAWI-2 promotes optineurin translocation into the nucleus and causes G2/M arrest. PAWI-2 reverses cancer stemness and overcomes drug resistance in an integrin β3 KRAS-dependent human pancreatic cancer stem cells (hPCSCs). PAWI-2 inhibits growth of tumors from hPCSCs in orthopic xenograft mice model[1][2]. | [IC 50]
Caspase 3; Caspase-7 | [References]
[1] Cashman JR, et al. Effect of PAWI-2 on pancreatic cancer stem cell tumors. Invest New Drugs. 2024 May 25. DOI:10.1007/s10637-024-01447-x
[2] Cheng J, et al. PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin β3-KRAS-dependent pancreatic cancer stem cells. Sci Rep. 2020 Jun 8;10(1):9162. DOI:10.1038/s41598-020-65804-5 |
|
|